Rome IV - Functional Pancreatic Sphincter of Oddi Disorder

Why use it

Recurrent acute pancreatitis without an identified cause (IRAP) represents approximately 20–30% of all acute pancreatitis admissions and carries significant morbidity. Identifying Functional Pancreatic SOD provides a positive, actionable diagnosis in a subset of IRAP patients and enables targeted treatment (endoscopic pancreatic sphincterotomy or dual sphincterotomy) that can reduce recurrence. The Rome IV E2 criteria operationalize the diagnostic approach, ensuring that objective evidence of sphincter dysfunction is required before intervention — protecting patients from unnecessary ERCP-based procedures in the absence of genuine outflow obstruction.

About

The Rome IV criteria for Functional Pancreatic Sphincter of Oddi Disorder (category E2) were established by the Rome Foundation Gallbladder and Sphincter of Oddi Disorders Committee and published in Gastroenterology in 2016. Functional Pancreatic SOD is defined as recurrent episodes consistent with acute pancreatitis — epigastric pain with amylase or lipase ≥3× the upper limit of normal (ULN), or cross-sectional imaging evidence of acute pancreatitis — occurring at least twice in the 12 months preceding evaluation, after thorough exclusion of all structural, metabolic, toxic, and genetic causes of recurrent pancreatitis, a negative endoscopic ultrasound (EUS), and objective evidence of sphincter dysfunction on manometry or secretin stimulation testing. The Rome IV revision substantially narrowed the criteria compared to Rome III: the previous Rome III classification into types I, II, and III based on pain alone was abandoned in favour of a single functional diagnosis requiring objective physiological evidence of sphincter dysfunction. This reflects the recognition that sphincter of Oddi manometry in symptom-only patients was associated with unacceptable complication rates and poor procedural outcomes, as demonstrated by the EPISOD trial (Cotton et al. 2014), which showed that sphincterotomy was no better than sham in pain-only SOD. Pancreatic SOD affects a small but important subset of patients with idiopathic recurrent acute pancreatitis (IRAP), estimated at 15–25% of cases where other causes have been exhaustively excluded. The pathophysiology involves elevated basal pancreatic sphincter pressure (>40 mmHg on manometry), impaired ductal drainage, and resultant intermittent obstruction to pancreatic outflow, leading to enzyme extravasation and parenchymal injury.

When to use

• Adults with recurrent acute pancreatitis (≥2 episodes in 12 months) in whom a thorough standard workup has failed to identify a cause
• After exclusion of gallstones and biliary microlithiasis (EUS, cholecystectomy if gallbladder present, endoscopic sampling for crystals)
• After exclusion of alcohol and toxic causes (history, serology)
• After exclusion of metabolic causes: hypertriglyceridemia (fasting lipids), hypercalcemia (serum calcium, PTH), hypercalcemia-related causes
• After exclusion of medications as a cause (review of current and recent medications)
• After exclusion of autoimmune pancreatitis (IgG4, imaging features)
• After exclusion of genetic causes in appropriate patients (PRSS1, SPINK1, CFTR mutations — especially younger patients or family history)
• After endoscopic ultrasound (EUS) is negative for structural causes: occult stones, pancreas divisum (relative), pancreatic duct anomalies, chronic pancreatitis changes, or mass lesions
• Before proceeding to sphincter of Oddi manometry or secretin stimulation test — these investigations carry procedure-related risk and should only follow complete standard exclusion
• NOT applicable when a definitive alternative cause of pancreatitis has been identified
• NOT validated for biliary-type pain without pancreatitis — use Rome IV E1b (Functional Biliary SOD) for that presentation

Formula

Pearls & pitfalls

• The EPISOD trial (2014, NEJM) was the pivotal study that reshaped the diagnostic approach to SOD — it demonstrated that sphincterotomy (biliary, pancreatic, or both) was NO better than sham procedure in patients with pain only (Rome III type III SOD). This led Rome IV to REQUIRE objective pancreatitis episodes, not pain alone, for the E2 diagnosis.
• EUS is mandatory before manometry — it identifies occult microlithiasis, early chronic pancreatitis, duct anomalies, and small pancreatic masses that standard CT or MRI may miss. In one series, EUS changed management in 40% of IRAP patients who had prior negative imaging.
• Pancreas divisum is present in approximately 7–10% of the general population and is found more commonly in IRAP. Rome IV acknowledges that pancreas divisum with recurrent pancreatitis may represent a functionally obstructed minor papilla — this should be evaluated and treated separately from sphincter manometry.
• The criterion of amylase or lipase ≥3× ULN with pain is deliberately conservative — it reduces false-positive episodes from non-pancreatic amylase elevations (salivary, macroamylasemia) or asymptomatic lipase elevations from medications.
• Sphincter of Oddi manometry is the gold-standard diagnostic test but is technically demanding, carries a 5–30% rate of post-procedure pancreatitis (even in experienced hands), and should only be performed in centres with dedicated pancreatologists and daily manometry practice.
• The secretin stimulation test (secretin-enhanced MRCP or endoscopic secretin test) is a less invasive alternative to manometry — failure of the main pancreatic duct to dilate by <1 mm and/or delayed drainage (>10 min return to baseline) suggests outflow obstruction and supports the diagnosis with lower procedural risk.
• Hypertriglyceridemia is commonly missed — fasting triglycerides >1000 mg/dL can cause pancreatitis, but levels of 200–1000 mg/dL are debated. Acute pancreatitis itself can transiently raise triglycerides — measure during a quiescent interval.
• Mutations in CFTR (even heterozygous), SPINK1 (N34S), and PRSS1 gain-of-function may predispose to pancreatitis without causing classic hereditary pancreatitis — these are important to exclude before labelling a case as functional.
• Post-procedure monitoring: following ERCP and pancreatic sphincterotomy, serum amylase at 2–4 hours post-procedure; if >3× ULN with pain, admit for observation. Most post-ERCP pancreatitis is mild but cases in SOD patients can be severe.
• Recurrence after sphincterotomy occurs in 30–40% of patients at 5 years — patients should be counselled about this, and re-evaluation of the diagnosis and repeat intervention may be required.

Next steps

Functional Pancreatic SOD confirmed (Rome IV E2): Referral to a high-volume center experienced in sphincter of Oddi manometry and pancreatic endotherapy. Endoscopic pancreatic sphincterotomy (minor papilla sphincterotomy if pancreas divisum also identified; major papilla dual biliary and pancreatic sphincterotomy for elevated pancreatic sphincter pressure) is the mainstay treatment — associated with reduction in recurrent pancreatitis episodes in 60–70% of appropriately selected patients in retrospective and prospective case series. Prophylactic pancreatic stent placement at the time of diagnostic/therapeutic ERCP reduces post-procedure pancreatitis risk. Rectal indomethacin 100 mg at time of ERCP reduces pancreatitis risk. Follow-up serum amylase/lipase at 2–4 hours post-procedure. Long-term follow-up at 3, 6, and 12 months to assess recurrence. If manometry elevated but patient declines endoscopic therapy: consider medical therapy with nifedipine 10–20 mg TID or hyoscine (limited evidence). Criteria not met / EUS not yet performed: Complete structural workup including EUS before any manometric assessment. If genetic testing not performed and clinical suspicion high: refer to genetics clinic for mutation analysis panel. If autoimmune pancreatitis not excluded: measure serum IgG4, consider tissue biopsy or steroid trial.

Evidence

Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. 2016;150(6):1420-1429.e2. PMID:27144631. Primary Rome IV reference for E2 Functional Pancreatic SOD. Cotton PB, Durkalski V, Romagnuolo J et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014;311(20):2101-2109. PMID:24867013 — pivotal negative RCT reshaping Rome IV E2. Coté GA et al. Recurrent acute pancreatitis and sphincter of Oddi dysfunction. Gastroenterology. 2016;150(6):1543-1553. Levy MJ, Geenen JE. Idiopathic acute recurrent pancreatitis. Am J Gastroenterol. 2001;96(9):2540-2555.

References

1. Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. 2016;150(6):1420-1429.e2. — link
2. Cotton PB, Durkalski V, Romagnuolo J et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability: the EPISOD randomized clinical trial. JAMA. 2014;311(20):2101-2109. — link
3. Drossman DA (ed). Rome IV: Functional Gastrointestinal Disorders. 4th ed. Raleigh, NC: Rome Foundation; 2016. — link
4. Coté GA et al. Recurrent acute pancreatitis and sphincter of Oddi dysfunction: a systematic review. Gastroenterology. 2016;150(6):1543-1553. — link
5. Levy MJ, Geenen JE. Idiopathic acute recurrent pancreatitis. Am J Gastroenterol. 2001;96(9):2540-2555. — link